...
首页> 外文期刊>Canadian Medical Association Journal: Journal de l'Association Medicale Canadienne >Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus
【24h】

Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus

机译:2型糖尿病患者的二甲双胍和低水平的促甲状腺激素

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Small cross-sectional studies have suggested that metformin, a first-line oral hypoglycemic agent, may lower thyroid-stimulating hormone (TSH) levels. Our objective was to determine whether the use of metformin monotherapy, when compared with sulfonylurea monotherapy, is associated with an increased risk of low TSH levels (< 0.4 mIU/L) in patients with type 2 diabetes mellitus.Methods: Using the Clinical Practice Research Datalink, we identified patients who began receiving metformin or sulfonylurea monotherapy between Jan. 1, 1988, and Dec. 31, 2012. We assembled 2 subcohorts of patients with treated hypothyroidism or euthyroidism, and followed them until Mar. 31, 2013. We used Cox proportional hazards models to evaluate the association of low TSH levels with metformin monotherapy, compared with sulfonylurea monotherapy, in each subcohort.Results: A total of 5689 patients with treated hypothyroidism and 59 937 euthyroid patients were included in the subcohorts. Among patients with treated hypothyroidism, 495 events of low TSH levels were observed during follow-up (incidence rate 119.7/1000 person-years). In the euthyroid group, 322 events of low TSH levels were observed (incidence rate 4.5/1000 person-years). Compared with sulfonylurea monotherapy, metformin monotherapy was associated with a 55% increased risk of low TSH levels in patients with treated hypothyroidism (incidence rate 79.5/1000 person-years v. 125.2/1000 person-years, adjusted hazard ratio [HR] 1.55, 95% confidence interval [CI] 1.09-2.20), with the highest risk in the 90-180 days after initiation (adjusted HR 2.30, 95% CI 1.00-5.29). No association was observed in euthyroid patients (adjusted HR 0.97, 95% CI 0.69-1.36).Interpretation: In this longitudinal population-based study, metformin use was associated with an increased incidence of low TSH levels in patients with treated hypothyroidism, but not in euthyroid patients. The clinical consequences of this need further investigation.
机译:背景:小型横断面研究表明,二甲双胍是口服一线降糖药,可能会降低甲状腺刺激激素(TSH)水平。我们的目的是确定二甲双胍单药治疗与磺酰脲类单药治疗相比是否与2型糖尿病患者低TSH水平(<0.4 mIU / L)的风险增加有关。数据链,我们确定了从1988年1月1日至2012年12月31日开始接受二甲双胍或磺脲类药物单一疗法的患者。我们收集了2个亚组的甲状腺功能减退或甲状腺功能减退患者,并随访至2013年3月31日。用Cox比例风险模型评估每个亚人群低TSH水平与二甲双胍单药治疗与磺酰脲单药治疗的相关性。结果:亚队列中共纳入5689例甲状腺功能减退患者和59 937例甲状腺功能正常患者。在接受甲状腺功能减退治疗的患者中,随访期间观察到495例低TSH水平事件(发生率119.7 / 1000人年)。在甲状腺正常组中,观察到322例低TSH水平的事件(发生率4.5 / 1000人年)。与甲磺酰脲单药治疗相比,二甲双胍单药治疗甲状腺功能减退症患者的低TSH水平风险增加55%(发生率79.5 / 1000人年v。125.2 / 1000人年,调整后的危险比[HR] 1.55, 95%置信区间[CI] 1.09-2.20),在开始后90-180天内具有最高风险(调整后的HR 2.30,95%CI 1.00-5.29)。在甲状腺功能正常的患者中未观察到相关性(校正后的HR 0.97,95%CI 0.69-1.36)。解释:在这项基于人群的纵向研究中,二甲双胍的使用与甲状腺功能减退症患者低TSH水平的发生率增加相关,但无相关性在甲状腺功能正常的患者中。这种临床后果需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号